Sorrento Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2016 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Sorrento Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2016 to Q2 2023.
  • Sorrento Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2023 was -1.02K %, a 346% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 -1.02K -1.44K -346% Jun 30, 2023
Q1 2023 1.72K +1.33K +336% Mar 31, 2023
Q4 2022 446 +93.6 +26.6% Dec 31, 2022
Q3 2022 391 +112 +40.3% Sep 30, 2022
Q2 2022 416 +184 +79.2% Jun 30, 2022
Q1 2022 395 +167 +73.1% Mar 31, 2022
Q4 2021 353 +58.7 +20% Dec 31, 2021
Q3 2021 279 -88.6 -24.1% Sep 30, 2021
Q2 2021 232 -324 -58.3% Jun 30, 2021
Q1 2021 228 -450 -66.4% Mar 31, 2021
Q4 2020 294 -325 -52.5% Dec 31, 2020
Q3 2020 368 -56.1 -13.2% Sep 30, 2020
Q2 2020 556 +277 +99.2% Jun 30, 2020
Q1 2020 678 +499 +278% Mar 31, 2020
Q4 2019 619 +491 +387% Dec 31, 2019
Q3 2019 424 +316 +294% Sep 30, 2019
Q2 2019 279 +157 +128% Jun 30, 2019
Q1 2019 179 +9.44 +5.56% Mar 31, 2019
Q4 2018 127 -130 -50.5% Dec 31, 2018
Q3 2018 107 -272 -71.7% Sep 30, 2018
Q2 2018 123 -230 -65.3% Jun 30, 2018
Q1 2018 170 -114 -40.2% Mar 31, 2018
Q4 2017 257 +24.5 +10.5% Dec 31, 2017
Q3 2017 379 +204 +116% Sep 30, 2017
Q2 2017 353 +205 +138% Jun 30, 2017
Q1 2017 284 +157 +123% Mar 31, 2017
Q4 2016 233 Dec 31, 2016
Q3 2016 175 Sep 30, 2016
Q2 2016 148 Jun 30, 2016
Q1 2016 127 Mar 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.